Damien C Weber1, Fritz Murray2, Christophe Combescure3, Valentin Calugaru4, Claire Alapetite4, Francesca Albertini2, Stephanie Bolle5, Farid Goudjil4, Alessia Pica2, Marc Walser2, Hamid Mammar4, Barbara Bachtiary2, Tony Lomax6, Georges Noël7, Rémi Dendale4, Loic Feuvret8. 1. Center for Proton Therapy, Paul Scherrer Institute, ETH Domain, Villigen, Switzerland; Radiation Oncology Department, University Hospital of Bern, Switzerland; Radiation Oncology Department, University Hospital of Zürich, Switzerland. Electronic address: damiencharles.weber@uzh.ch. 2. Center for Proton Therapy, Paul Scherrer Institute, ETH Domain, Villigen, Switzerland. 3. Service d'épidémiologie clinique, Hôpitaux Universitaires de Genève, Switzerland; Clinical Research Center, Faculty of Medicine, University of Geneva, Switzerland. 4. Institut Curie Protontherapy Center, Orsay, France. 5. Department of Radiation Oncology, Gustave Roussy, Villejuif, France. 6. Center for Proton Therapy, Paul Scherrer Institute, ETH Domain, Villigen, Switzerland; Department of Physics, ETH, Zürich, Switzerland. 7. Department of Radiation Oncology, Centre Paul Strass, Strasbourg, France. 8. Institut Curie Protontherapy Center, Orsay, France; Department of Radiation Oncology, Hôpital Pitié-Salpêtrière-Charles-Foix, APHP, Paris, France.
Abstract
BACKGROUND AND PURPOSE: Skull-base chondrosarcoma (ChSa) is a rare bone tumor and the outcome of patients with this malignancy has been documented only in a limited number of series with a restricted number of patients. OBJECTIVE: This study was conducted to assess the outcome and prognostic factors of a large cohort of ChSa patients treated with radiotherapy in two proton therapy centers. MATERIALS AND METHODS: From 1996 to 2015, 251 (male, 43.4%) patients (mean age, 42.0 ± 16.2 years) were treated with protons with (n = 135; 53.8%) or without photons (n = 116; 46.2%). Median delivered dose was 70.2 GyRBE. Failure-free survival (FFS), overall survival (OS) and CTCAE grade ≥3 toxicity free survival (TFS) were calculated using the Kaplan-Meier method. RESULTS: After a median follow-up of 88.0 months for surviving patients, local and distant failures were observed in 12 (4.8%) and 4 (1.6%) patients, respectively. Late failures >6 years were observed in 4 (33.3%) patients. The estimated 7-year FFS was 93.1%. Twenty-five (10%) patients died. The estimated 7-year OS was 93.6%. Tumor volume (p = 0.006) and optic pathway compression (p = 0.027) were significantly associated with the risk of treatment failure on univariate analysis. Treatment failure was significantly associated with a higher risk of death (hazard ratio = 126). The estimated 7-year TFS was 84.2%. CONCLUSIONS: The outcome of skull-base ChSa patients treated with high-dose protons with or without photons is excellent, particularly for patients with small tumors with no optic pathway compression. Treatment failure was however associated with a significantly increased risk of death.
BACKGROUND AND PURPOSE: Skull-base chondrosarcoma (ChSa) is a rare bone tumor and the outcome of patients with this malignancy has been documented only in a limited number of series with a restricted number of patients. OBJECTIVE: This study was conducted to assess the outcome and prognostic factors of a large cohort of ChSa patients treated with radiotherapy in two proton therapy centers. MATERIALS AND METHODS: From 1996 to 2015, 251 (male, 43.4%) patients (mean age, 42.0 ± 16.2 years) were treated with protons with (n = 135; 53.8%) or without photons (n = 116; 46.2%). Median delivered dose was 70.2 GyRBE. Failure-free survival (FFS), overall survival (OS) and CTCAE grade ≥3 toxicity free survival (TFS) were calculated using the Kaplan-Meier method. RESULTS: After a median follow-up of 88.0 months for surviving patients, local and distant failures were observed in 12 (4.8%) and 4 (1.6%) patients, respectively. Late failures >6 years were observed in 4 (33.3%) patients. The estimated 7-year FFS was 93.1%. Twenty-five (10%) patients died. The estimated 7-year OS was 93.6%. Tumor volume (p = 0.006) and optic pathway compression (p = 0.027) were significantly associated with the risk of treatment failure on univariate analysis. Treatment failure was significantly associated with a higher risk of death (hazard ratio = 126). The estimated 7-year TFS was 84.2%. CONCLUSIONS: The outcome of skull-base ChSa patients treated with high-dose protons with or without photons is excellent, particularly for patients with small tumors with no optic pathway compression. Treatment failure was however associated with a significantly increased risk of death.
Authors: Adam L Holtzman; James E Bates; Christopher G Morris; Michael S Rutenberg; Daniel J Indelicato; Daryoush Tavanaiepour; William M Mendenhall Journal: J Neurol Surg B Skull Base Date: 2021-03-09
Authors: Sara Rosas; Francesca M Belosi; Nicola Bizzocchi; Till Böhlen; Stefan Zepter; Petra Morach; Antony J Lomax; Damien C Weber; Jan Hrbacek Journal: Br J Radiol Date: 2020-01-30 Impact factor: 3.039
Authors: Paolo Palmisciano; Ali S Haider; Mohammadmahdi Sabahi; Chibueze D Nwagwu; Othman Bin Alamer; Gianluca Scalia; Giuseppe E Umana; Aaron A Cohen-Gadol; Tarek Y El Ahmadieh; Kenny Yu; Omar N Pathmanaban Journal: Cancers (Basel) Date: 2021-11-26 Impact factor: 6.639
Authors: Hussain AlHussain; Ali Balbaid; Robert Malyapa; Majid AlOthman; Yasser A Bahadur; Mutahir A Tunio; Mushabbab Al Asiri Journal: Saudi Med J Date: 2019-09 Impact factor: 1.484